Vanda Pharmaceuticals Inc (NASDAQ:VNDA) shares, rose in value on Thursday, April 04, with the stock price up by 5.35% to the previous day’s close as strong demand from buyers drove the stock to $5.32.
Actively observing the price movement in the recent trading, the stock is buoying the session at $5.05. The value of beta (5-year monthly) is 0.76 whereas the PE ratio is 121.74 over 12-month period. Referring to stock’s 52-week performance, its high was $7.00, and the low was $3.30. On the whole, VNDA has fluctuated by 28.50% over the past month.
With the market capitalization of Vanda Pharmaceuticals Inc currently standing at about $306.11 million, investors are eagerly awaiting this quarter’s results, scheduled for May 01, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.05, which is expected to increase to $0.02 for fiscal year $0.01 and then to about -$0.48 by fiscal year 2025. Data indicates that the EPS growth is expected to be -75.00% in 2025, while the next year’s EPS growth is forecast to be -4,900.00%.
Analysts have estimated the company’s revenue for the quarter at $48.5 million, with a low estimate of $48.5 million and a high estimate of $48.5 million. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $188 million, representing a decrease of -2.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VNDA’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 3.37, with the price of VNDA currently trading nearly 34.93% and 32.19% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 76.54, while the 7-day volatility ratio is showing 10.87% which for the 30-day chart, stands at 5.40%. Furthermore, Vanda Pharmaceuticals Inc (VNDA)’s beta value is 0.75, and its average true range (ATR) is 0.32.
A comparison of Vanda Pharmaceuticals Inc (VNDA) with its peers suggests the former has fared considerably weaker in the market. VNDA showed an intraday change of 5.35% in today’s session so far, and over the past year, it shrunk by -22.22%%.
Data on historical trading for Vanda Pharmaceuticals Inc (NASDAQ:VNDA) indicates that the trading volumes over the past 10 days have averaged 6.37 million and over the past 3 months, they’ve averaged 1.78 million. According to company’s latest data on outstanding shares, there are 57.53 million shares outstanding.
Nearly 5.26% of Vanda Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 89.15% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.0 million shares as on Mar 15, 2024, resulting in a short ratio of 3.24. According to the data, the short interest in Vanda Pharmaceuticals Inc (VNDA) stood at 5.22% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 2.96 million. The stock has risen by 26.07% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VNDA stock heading into the next quarter.
